Application and method of IL-1a in establishing human gingival fibroblast oral anti-inflammatory model

A fibroblast and inflammation model technology, applied in animal cells, vertebrate cells, cell culture active agents, etc., can solve problems such as loss of efficacy, long delivery period, and poor stability of inflammation models

Pending Publication Date: 2020-05-12
GUANGDONG BOXI BIO TECH CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these two LPSs have the following two disadvantages in the construction of cell inflammation models: 1. The stability of the inflammation model is poor, and the experiment repetition rate is low, which often leads to conflicting evaluations on the anti-inflammatory effects of the same sample, making it impossible to accurately evaluate the oral cavity. Authenticity of care ingredients and product anti-inflammatory effects
2. LPS is unstable, relatively expensive, and has a long delivery period, especially Pg.LPS, and there are many disadvantages in the storage method of LPS, such as: the concentration of LPS must be greater than 2mg / ml when preparing, otherwise LPS Long-term storage can adhere to the tube wall, and the effective ingredients will be reduced and lose their effectiveness
The latter, these often bring a lot of inconvenience to experimental operators and enterprises

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application and method of IL-1a in establishing human gingival fibroblast oral anti-inflammatory model
  • Application and method of IL-1a in establishing human gingival fibroblast oral anti-inflammatory model
  • Application and method of IL-1a in establishing human gingival fibroblast oral anti-inflammatory model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0034] (1) Effects of different concentrations of stimulants on the viability of human gingival fibroblasts: set up a blank group, a control group and an experimental group. The following three substances were selected as the stimulus: IL-1a, Ecoli.LPS and Pg.LPS. Among them, three substances are divided into 3-4 concentrations for concentration exploration. The specific concentrations are shown in the table below. IL-1a is set at 1ng / ml, 5ng / ml, 10ng / ml, 15ng / ml; Ecoli.LPS is set at 1ug / ml, 10ug / ml, 50ug / ml, 100ug / ml; Pg.LPS is set at 1ug / ml, 10ug / ml ml, 50ug / ml, 100ug / ml.

[0035] (2) Inflammation model induced by IL-1a in human gingival fibroblasts: set up control group and experimental group. 2×10 human gingival fibroblasts 5 Cells / well were seeded in a 24-well plate, and 2 mL of high-DMEM medium containing 10% FBS was added to each well, and placed at 37±1°C, 5±1% CO 2 , 95% relative humidity incubator, and the cell plating rate reached between 40% and 60% at 24 hour...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application and a method of IL-1a in establishing a human gingival fibroblast oral anti-inflammatory model and the human gingival fibroblast inflammation model. The human gingival fibroblast oral anti-inflammatory model provided by the invention can more comprehensively reflect efficacy of oral care products, and provides a more objective, scientific and accurate evaluation mode for evaluating efficacy of oral anti-aging products.

Description

technical field [0001] The invention belongs to the technical field of detection of safety and efficacy of oral care products, and in particular relates to a method for establishing a human gingival fibroblast inflammation model of IL-1a, an application of IL-1a in establishing a human gingival fibroblast inflammation model, and an IL-1a method for establishing a human gingival fibroblast inflammation model. Inflammation model of human gingival fibroblasts established by -1a. Background technique [0002] Inflammation is a pathological process in which living tissue responds mainly to defense against injury or infection. In the inflammatory process, on the one hand, damage factors can directly and indirectly cause tissue and cell damage, and on the other hand, they can also cause vascular congestion and exudative reactions, which exist in the form of diluting, killing and surrounding damaged tissues. In the past ten years, with the development of biotechnology, when people ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/077G01N33/74G01N33/68
CPCC12N5/0656G01N33/74G01N33/6869G01N33/6866C12N2501/2301C12N2500/02C12N2523/00G01N2800/7095G01N2333/72G01N2333/7151G01N2333/7155
Inventor 杨文娟卢永波张勇杰
Owner GUANGDONG BOXI BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap